Middlemore Hospital's Cath Lab, Coronary Care Unit and Middlemore Clinical Trials representing New Zealand at the TCT2019 Conference

The Cath Lab; Coronary Care Unit (CCU) and Middlemore Clinical Trials (MMCT) have been involved in a novel stent trial this year, recruiting 10 trial participants to-date (target of 7 participants) making Middlemore Hospital the highest recruiting site for the trial. Dr Douglas Scott (Primary Investigator) and Kavita Gounder (Primary Research Nurse – MMCT) have therefore been invited by the Trial Sponsor (Elixir Medical Corporation) to attend the TCT2019 Conference.

Sep 27, 2019

27/09/2019

The Cath Lab; Coronary Care Unit (CCU) and Middlemore Clinical Trials (MMCT) have been involved in a novel stent trial this year, recruiting 10 trial participants to-date (target of 7 participants) making Middlemore Hospital the highest recruiting site for the trial. Dr Douglas Scott (Primary Investigator) and Kavita Gounder (Primary Research Nurse – MMCT) have therefore been invited by the Trial Sponsor (Elixir Medical Corporation) to attend the Transcatheter Cardiovascular Therapeutics (TCT) 2019 Conference in San Francisco.

TCT 2019 is a 5-day conference (25-29 September 2019) bringing the latest knowledge and research in interventional cardiology with over 20 highly anticipated, late-breaking clinical trial presentations and demonstrations of the newest innovation in devices, drugs, and emerging therapies. At this conference, Kavita and Douglas will be sharing ideas with innovators and researchers from around the world.

The DynamX Sirolimus trial is an early phase trial evaluating a novel thin strut metallic coronary device (the Elixir DynamXTM Sirolimus Eluting Coronary Bioadaptor System) in de novo native coronary artery lesions using clinical and imaging endpoints. The study involves a complex procedure visit and 3 clinical follow-up visits. Due to the narrow recruitment window (shortly after presentation of the event), the trial requires exceptional teamwork and communication between the Cath lab; CCU and MMCT. We would like to applaud everyone involved in the trial (some of the core staff pictured) as well as express gratitude to the trial participants. We wouldn’t be able to develop the next generation of modern medicines without their contribution to research.

MMCT looks forward to working with the dynamic team in the Cath lab and CCU and to continue bringing future cutting edge clinical trials to Middlemore Hospital and its patients.

Pai te mahi, Cath Lab; CCU and MMCT!

 

About Us

Middlemore Clinical Trials (MMCT) is New Zealand's largest clinical trials site, which offers world-class facilities, excellent audited procedures, and a fully integrated research unit.

Our Contacts